Cancer-specific dysregulation (reduced expression or genomic loss) of several miRNAs (26a, 98, 124, 214, 101, 137, and let-7) can lead to aberrant histone modifications and appears to be one of the major causes of EZH2 overexpression in several types of cancer (prostate, breast, bladder, gastric, lung, and renal) [43] (Figure 1). Here, EZH2 is linked to cancer.